This Article Full Text Full Text (PDF) All Versions of this Article: 110/21/3349    most recent 01.CIR.0000147774.90396.EDv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pleiner, J. Articles by Wolzt, M. Search for Related Content PubMed PubMed Citation Articles by Pleiner, J. Articles by Wolzt, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB NITROGLYCERIN Related Collections Endothelium/vascular type/nitric oxide Other Vascular biology Related Article

(Circulation. 2004;110:3349-3354.)
© 2004 American Heart Association, Inc.

Vascular Medicine

Simvastatin Prevents Vascular Hyporeactivity During Inflammation

Johannes Pleiner, MD; Georg Schaller, MD; Friedrich Mittermayer, MD; Stefan Zorn, MS; Claudia Marsik, MD; Stefan Polterauer, MS; Stylianos Kapiotis, MD; Michael Wolzt, MD

From the Department of Clinical Pharmacology (J.P., G.S., F.M., S.Z., C.M., S.P., M.W.), Institute for Medical and Chemical Laboratory Diagnostics (C.M., S.K.), Medical University of Vienna, Vienna, Austria.

Correspondence to Dr Michael Wolzt, Department of Clinical Pharmacology, Allgemeines Krankenhaus Wien, Währinger Gürtel 18-20, A-1090 Vienna, Austria. E-mail michael.wolzt{at}meduniwien.ac.at

Received June 15, 2004; revision received August 18, 2004; accepted September 13, 2004.

Background— There is growing evidence that statins exert anti-inflammatory and antioxidative vascular actions that are independent of lipid lowering. We tested whether hyporeactivity to the endothelium-dependent vasodilator acetylcholine (ACh) and the vasoconstrictor norepinephrine (NE) during acute experimental inflammation could be prevented by simvastatin.

Methods and Results— In a randomized, placebo-controlled, parallel group study, forearm blood flow (FBF) responses to NE, ACh, and the endothelium-independent vasodilator nitroglycerin (NTG) were assessed at baseline, after 4 days of simvastatin 80 mg PO or placebo treatment, and during Escherichia coli endotoxin (lipopolysaccharide [LPS])–induced inflammation in 20 healthy volunteers. Additionally, markers of inflammation and neutrophil oxidative burst were assessed. Simvastatin and placebo had no effect on FBF or oxidative/inflammatory markers. LPS administration decreased the responses of FBF to NE by 43% (P<0.05) and decreased responses to ACh by 48% (P<0.05) but did not decrease FBF responses to NTG. Simvastatin completely preserved responses to NE and to ACh. The LPS-induced increases in neutrophil oxidative burst and plasma tumor necrosis factor- concentrations were mitigated by simvastatin (P<0.05 versus placebo).

Conclusions— This study demonstrates potent vasoprotective properties of high-dose simvastatin during endotoxemia that may be useful for patients with acute systemic inflammation and associated vascular hyporeactivity.

Key Words: inflammation • endothelium • vasoconstriction • statins

Related Article:

Circulation 2004 110: 3289. [Extract] [Full Text]

This article has been cited by other articles:

				V. Chopra and S. A. Flanders Does Statin Use Improve Pneumonia Outcomes? Chest, November 1, 2009; 136(5): 1381 - 1388. [Abstract] [Full Text] [PDF]

				F. Gao, L. Linhartova, A. McD. Johnston, and D. R. Thickett Statins and sepsis Br. J. Anaesth., March 1, 2008; 100(3): 288 - 298. [Abstract] [Full Text] [PDF]

				R. Mahajan, R. Gupta, and A. Sharma Beneficial Effects of Statin Therapy on Infection Related Mortality in Patients with Atherosclerotic and Cardiovascular Disease Anesth. Analg., January 1, 2008; 106(1): 352 - 352. [Full Text] [PDF]

				H. Shao, Y. Shen, H. Liu, G. Dong, J. Qiang, and H. Jing Simvastatin Suppresses Lung Inflammatory Response in a Rat Cardiopulmonary Bypass Model Ann. Thorac. Surg., December 1, 2007; 84(6): 2011 - 2018. [Abstract] [Full Text] [PDF]

				C. Vlachopoulos, K. Aznaouridis, A. Dagre, C. Vasiliadou, C. Masoura, E. Stefanadi, J. Skoumas, C. Pitsavos, and C. Stefanadis Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects Eur. Heart J., September 1, 2007; 28(17): 2102 - 2109. [Abstract] [Full Text] [PDF]

				A. Yilmaz, C. Reiss, A. Weng, I. Cicha, C. Stumpf, A. Steinkasserer, W. G. Daniel, and C. D. Garlichs Differential effects of statins on relevant functions of human monocyte-derived dendritic cells J. Leukoc. Biol., March 1, 2006; 79(3): 529 - 538. [Abstract] [Full Text] [PDF]

				A. Warnholtz, S. Genth-Zotz, and T. Munzel Should Treatment of Sepsis Include Statins? Circulation, April 12, 2005; 111(14): 1735 - 1737. [Full Text] [PDF]

				S. Steiner, W. S. Speidl, J. Pleiner, D. Seidinger, G. Zorn, C. Kaun, J. Wojta, K. Huber, E. Minar, M. Wolzt, et al. Simvastatin Blunts Endotoxin-Induced Tissue Factor In Vivo Circulation, April 12, 2005; 111(14): 1841 - 1846. [Abstract] [Full Text] [PDF]